LTFS
ACAD icon

Ladenburg Thalmann Financial Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$987K Buy
23,445
+427
+2% +$18.6K 0.01% 1295
2019
Q3 		$829K Buy
23,018
+10,460
+83% +$317K 0.01% 1370
2019
Q2 		$337K Sell
12,558
-1,249
-9% -$31.9K ﹤0.01% 2052
2019
Q1 		$372K Buy
13,807
+708
+5% +$16.5K ﹤0.01% 1912
2018
Q4 		$225K Sell
13,099
-281
-2% -$5.46K ﹤0.01% 2155
2018
Q3 		$279K Buy
13,380
+6,658
+99% +$105K ﹤0.01% 2042
2018
Q2 		$145K Hold
6,722
– – ﹤0.01% 2475
2018
Q1 		$145K Buy
6,722
+573
+9% +$15.9K ﹤0.01% 2475
2017
Q4 		$186K Sell
6,149
-360
-6% -$11.5K ﹤0.01% 2256
2017
Q3 		$247K Buy
6,509
+2,358
+57% +$76.7K ﹤0.01% 1944
2017
Q2 		$116K Buy
4,151
+1,590
+62% +$47.4K ﹤0.01% 2421
2017
Q1 		$88K Buy
2,561
+561
+28% +$19.8K ﹤0.01% 2482
2016
Q4 		$59K Buy
2,000
+123
+7% +$3.25K ﹤0.01% 2715
2016
Q3 		$59K Buy
1,877
+739
+65% +$25.1K ﹤0.01% 2662
2016
Q2 		$36K Buy
1,138
+149
+15% +$4.99K ﹤0.01% 2927
2016
Q1 		$27K Sell
989
-142
-13% -$3.1K ﹤0.01% 3034
2015
Q4 		$40K Sell
1,131
-31
-3% -$1.09K ﹤0.01% 2725
2015
Q3 		$38K Buy
1,162
+187
+19% +$7.78K ﹤0.01% 2653
2015
Q2 		$41K Buy
975
+595
+157% +$23K ﹤0.01% 2719
2015
Q1 		$12K Buy
380
+265
+230% +$9.11K ﹤0.01% 3491
2014
Q4 		$4K Hold
115
– – ﹤0.01% 3794
2014
Q3 		$3K Hold
115
– – ﹤0.01% 3550
2014
Q2 		$3K Buy
115
+90
+360% +$1.88K ﹤0.01% 3511
2014
Q1 		$1K Sell
25
-620
-96% -$15.7K ﹤0.01% 3600
2013
Q4 		$16K Buy
645
+620
+2,480% +$14.6K ﹤0.01% 2654
2013
Q3 		$1K Buy
+25
New +$523 ﹤0.01% 3530

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ACAD Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Acadia Pharmaceuticals (ACAD) stake by 1.9% in Q4 2019, buying an estimated $18.6K and bringing the position to 23,445 shares worth $987K. The position accounts for 0.01% of the portfolio, ranked #1295.

Ladenburg Thalmann Financial Services first reported a position in ACAD in Q3 2013 and has held it in 26 quarters since. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 23,445 shares of Acadia Pharmaceuticals worth $987K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 427 Acadia Pharmaceuticals shares in Q4 2019, an estimated $18.6K.
  • Acadia Pharmaceuticals made up 0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1295 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 26 quarters since.
  • 273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.